FDA
-
-
-
-
-
-
-
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
-
-
-
-
-
-
-
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
-
-
-
-
-
-
-
NextCure Inc. (NXTC) Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
-
-
-
-
-
-
-
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting
-
-
-
-
-
-
-
NextCure Inc. (NXTC) Announces Dr. Han Myint Appointed as Chief Medical Officer
-
-
-
-
-
-
-
NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic
-
-
-
-
-
-
-
NextCure Reports Second Quarter 2019 Financial Results
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

